Acetyl-TP53 (K373) Antibody

What is the biological significance of p53 acetylation at K373?

Acetylation of p53 at lysine 373 (K373) represents a critical post-translational modification that significantly influences p53's function as a tumor suppressor. Research demonstrates that K373 acetylation enhances p53's transcriptional activity and alters its binding affinity for target genes. Specifically, acetylation at K373 leads to hyperphosphorylation of p53 NH2-terminal residues and enhances interaction with promoters for which p53 possesses low DNA binding affinity, particularly those contained in proapoptotic genes . This modification plays a decisive role in cell fate determination after DNA damage, with K373 acetylation promoting apoptotic responses rather than cell cycle arrest . Unlike acetylation at other sites (such as K320), K373 acetylation intensifies rather than prevents cell death, functioning as a molecular switch that helps determine cellular responses to genotoxic stress .

How can researchers reliably detect p53 acetylation at K373?

Detection of p53 acetylation at K373 requires specific antibodies that recognize this modified epitope. Western blotting represents the most common detection method, with recommended dilutions typically ranging from 1:500-1:2000 . For optimal results, researchers should:

• Include positive controls such as cells treated with DNA-damaging agents (e.g., etoposide) combined with deacetylase inhibitors like trichostatin A (TSA)

• Use appropriate negative controls including untreated cells

• Validate antibody specificity using acetylation-deficient p53 mutants

• Consider complementary techniques such as immunofluorescence or flow cytometry for single-cell analysis

Immunocytochemistry/Immunofluorescence protocols have been validated using HepG2 cells treated with etoposide (30μg/ml for 8hr) followed by TSA (500ng/ml for 4hr) , providing a methodological framework for researchers to adapt to their specific experimental systems.

What treatments can induce p53 acetylation at K373?

Several treatments have been documented to reliably induce p53 acetylation at K373:

• DNA-damaging agents:

  • Etoposide (topoisomerase inhibitor): 25-30μg/ml for 5-8 hours

  • Adozelesin and bizelesin (DNA-alkylating agents)

• Deacetylase inhibitors:

  • Trichostatin A (HDAC inhibitor): 500ng/ml for 4 hours

  • Nicotinamide (SIRT inhibitor)

Research indicates that different DNA-damaging agents affect the kinetics and extent of K373 acetylation differently. For instance, the DNA cross-linking agent bizelesin induces K373 acetylation more rapidly than the monofunctional agent adozelesin . The dose of DNA-damaging agents also influences the degree of K373 acetylation, with higher doses generally leading to increased acetylation levels . This suggests that K373 acetylation functions as a "sensor" for both the type and extent of DNA damage.

How does acetylation at K373 influence p53's interactions with other proteins?

Acetylation at K373 dramatically alters p53's protein interaction landscape, influencing cellular outcomes through distinct protein-protein interactions:

• Increased coactivator binding: Acetylated p53 at K373 displays significantly stronger affinity for p300 compared to p53 acetylated at other sites (e.g., K320)

• Enhanced deacetylase recruitment: K373-acetylated p53 strongly coprecipitates with deacetylases including HDAC1 and SIRT1, stabilizing these interactions for extended periods (at least 12 hours after treatment)

• Differential cofactor interactions: K373 acetylation creates a unique interaction profile distinct from other acetylation sites, contributing to p53's functional divergence in cell fate decisions

To methodologically investigate these interactions, researchers should:

• Use co-immunoprecipitation with Acetyl-TP53 (K373) antibodies

• Compare interaction profiles across multiple acetylation sites

• Analyze temporal dynamics of interactions following DNA damage

• Consider chromatin immunoprecipitation to assess promoter-specific recruitment of cofactors

These protein interactions help explain how K373 acetylation promotes apoptotic rather than cell survival pathways .

What is the relationship between p53 K373 acetylation and other post-translational modifications?

Research reveals complex crosstalk between K373 acetylation and other p53 modifications:

These interconnections create what researchers have termed "p53 cassettes" - specific combinations of post-translational modifications that collectively determine p53 function . This concept parallels the "histone code" hypothesis, suggesting that p53 activity is orchestrated through precise modification patterns rather than individual modifications in isolation .

To methodologically address this complexity, researchers should consider:

• Using multiple modification-specific antibodies simultaneously

• Employing mass spectrometry to catalog comprehensive modification patterns

• Developing time-course analyses to track modification sequences

• Creating modification-specific mutants to assess functional dependencies

How can researchers distinguish between direct and indirect effects when studying p53 K373 acetylation?

Distinguishing direct consequences of K373 acetylation from secondary effects requires rigorous experimental design:

• Use acetylation mimics: Compare glutamine substitution mutants (p53Q373) with native p53 to isolate acetylation-specific effects

• Employ true acetylation detection: Use site-specific acetylation antibodies to confirm findings from mimics with endogenously acetylated p53

• Conduct time-course analyses: Track the temporal sequence of events following K373 acetylation induction to separate primary from secondary effects

• Perform gene expression profiling: Compare transcriptional profiles between p53Q373 and native p53 to identify direct transcriptional targets

• Combine with deacetylase inhibition: Use specific inhibitors of HDACs and SIRTs to maintain acetylation and isolate its effects

Research demonstrates that p53Q373 (acetylation mimic) directly enhances interaction with promoters having low p53 binding affinity and increases HDAC1 recruitment , providing a methodological framework for distinguishing direct acetylation effects.

What are the critical controls when using Acetyl-TP53 (K373) antibodies in experiments?

Rigorous experimental design with Acetyl-TP53 (K373) antibodies requires these essential controls:

Positive Controls:

• Cells treated with DNA damage inducers (etoposide, 30μg/ml for 8hr) plus deacetylase inhibitors (TSA, 500ng/ml for 4hr)

• Recombinant acetylated p53 proteins (when available)

Negative Controls:

• Untreated cells (baseline acetylation levels)

• p53-null cell lines (antibody specificity verification)

• K373R mutant p53 (non-acetylatable variant)

• Acetylation-blocking treatments (HDAC/acetyltransferase inhibitors)

Antibody Controls:

• Isotype control antibodies (e.g., rabbit monoclonal IgG)

• Peptide competition assays using synthesized acetyl-peptides derived from p53 around K373

• Secondary antibody-only controls

Methodological Controls:

• Multiple detection methods (Western blot, immunofluorescence, flow cytometry)

• Different antibody clones recognizing the same modification

• Dilution series to ensure signal linearity

Flow cytometry experiments specifically benefit from including unlabelled samples alongside isotype controls to establish proper gating strategies and distinguish true signals from background .

How should researchers optimize immunofluorescence protocols for detecting acetylated p53 at K373?

Optimizing immunofluorescence for acetylated p53 at K373 detection requires careful protocol adjustment:

• Fixation and Permeabilization:

  • Fix cells with 4% paraformaldehyde for 10 minutes

  • Permeabilize with 0.1% Triton X-100 for 5 minutes

  • Alternative: Fix and permeabilize with 90% methanol for flow cytometry applications

• Blocking:

  • Block with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1 hour

  • Ensure blocking buffer matches the host species of the secondary antibody

• Antibody Incubation:

  • Use Acetyl-TP53 (K373) antibody at 1:250 dilution

  • Incubate overnight at 4°C for optimal signal-to-noise ratio

  • For double-staining, include other markers like alpha-tubulin (1:250 dilution)

• Signal Enhancement:

  • Use fluorophore-conjugated secondary antibodies (e.g., Alexa Fluor® 488)

  • Include DAPI nuclear counterstain

  • Consider tyramide signal amplification for low-abundance targets

• Analysis Considerations:

  • Compare nuclear vs. cytoplasmic localization

  • Quantify signal intensity across treatment conditions

  • Use Z-stack imaging for three-dimensional distribution analysis

Using these optimized protocols, researchers can effectively visualize the subcellular localization and relative abundance of K373-acetylated p53 in response to various treatments.

What are the key considerations for quantifying p53 K373 acetylation levels?

Accurate quantification of p53 K373 acetylation requires attention to several methodological factors:

Western Blot Quantification:

• Always normalize acetylated p53 signal to total p53 levels

• Use internal loading controls (β-actin, GAPDH) for sample normalization

• Employ validated antibodies at recommended dilutions (1:500-1:2000)

• Generate standard curves using purified proteins when possible

• Use digital image analysis software with background subtraction

Flow Cytometry Quantification:

• Collect minimum 5,000 events per sample

• Use 488nm laser excitation with appropriate bandpass filters (e.g., 585/42)

• Report median fluorescence intensity rather than percent positive

• Include isotype and unstained controls for accurate gating

• Consider dual staining for total p53 and acetylated p53

Mass Spectrometry Approaches:

• Use trichostatin A and nicotinamide treatment before isolation to increase yield of acetylated forms

• Consider targeted multiple reaction monitoring (MRM) for sensitive quantification

• Use stable isotope labeling for relative quantification across samples

• Include synthetic acetylated peptide standards

When comparing acetylation levels across different experimental conditions, researchers should ensure consistent total p53 expression levels to avoid confounding effects from variable protein abundance.

How does p53 K373 acetylation influence gene expression programs?

Acetylation of p53 at K373 orchestrates distinct gene expression programs by altering p53's DNA binding affinity and cofactor recruitment:

Transcriptional Effects:

• K373 acetylation enhances p53 binding to low-affinity promoters, particularly those of proapoptotic genes

• It promotes recruitment of coactivators like p300

• It also enhances interaction with transcriptional repressors including HDAC1 and SIRT1

• p53Q373 (acetylation mimic) represses more genes (1,576) than p53Q320 (955)

Methodological Approaches:

• Gene Expression Analysis: Microarray or RNA-seq comparing wild-type vs. acetylation mimics

• ChIP-seq: Map genome-wide binding of acetylated p53 at K373

• Reporter Assays: Measure transcriptional activity at specific promoters

• RT-qPCR: Validate expression changes of key target genes

Research demonstrates that acetylation state influences target gene selectivity - K373 acetylation shifts the balance toward proapoptotic genes, while K320 acetylation favors cell cycle arrest genes like p21/WAF . This selectivity appears to be mediated through differential DNA binding affinity and cofactor recruitment.

How can researchers study the role of K373 acetylation in p53-mediated tumor suppression?

Investigating K373 acetylation in tumor suppression requires multiple complementary approaches:

Cell Culture Models:

• Compare p53-null cells reconstituted with wild-type p53 versus K373R (non-acetylatable) or K373Q (acetylation mimic) variants

• Assess cellular responses to DNA-damaging agents across these variants

• Determine long-term effects on genomic stability and transformation

Functional Assays:

• Colony formation assays to measure proliferation and survival

• Cell cycle analysis using flow cytometry

• Apoptosis assays (Annexin V, caspase activation)

• Drug sensitivity assays using chemotherapeutic agents

In Vivo Models:

• Generate knock-in mouse models with K373R mutations

• Assess tumor development in carcinogen-treated or genetically predisposed backgrounds

• Analyze tissue-specific requirements for K373 acetylation

Research demonstrates that p53Q373 expression sensitizes cells to apoptosis following treatment with DNA-damaging agents like bizelesin or etoposide , suggesting that K373 acetylation enhances p53's tumor suppressive functions by promoting cell death in response to genotoxic stress.

How does acetylation at K373 contribute to decisions between cell cycle arrest and apoptosis?

Acetylation at K373 plays a crucial role in determining cellular fate following DNA damage:

Mechanistic Insights:

• K373 acetylation promotes apoptosis while K320 acetylation favors cell cycle arrest

• p53Q373 (acetylation mimic) shows strong chemosensitizing effects with most cells undergoing apoptosis early after drug treatment

• K373 acetylation enhances binding to proapoptotic gene promoters that have lower affinity for p53

• It promotes hyperphosphorylation of p53 N-terminal residues, further influencing target gene selection

Experimental Approaches:

• Compare cellular outcomes between p53Q373 and p53Q320 expression following DNA damage

• Analyze binding profiles to cell cycle arrest vs. apoptotic promoters using ChIP

• Perform time-course analysis of cell death vs. growth arrest markers

• Use combination treatments with HDAC inhibitors to potentiate specific outcomes

Research demonstrates that when both K320 and K373 are mutated, the K320 mutation has a dominant effect in preventing cell death , suggesting a hierarchical relationship between these modifications in determining cell fate.

How does acetylation at K373 compare with other p53 acetylation sites?

Research reveals distinct functional profiles across different p53 acetylation sites:

Methodologically, researchers should:

• Use site-specific antibodies to distinguish individual acetylation events

• Consider combinatorial effects of multiple acetylation sites

• Employ acetylation mimics (K→Q) or acetylation-preventing mutants (K→R) for comparative studies

• Use mass spectrometry to catalog comprehensive acetylation patterns

The concept of "p53 cassettes" suggests that different combinations of acetylation sites work in concert to fine-tune p53 function , rather than individual modifications acting in isolation.

What are the technical challenges in detecting p53 K373 acetylation in tissues and primary cells?

Researchers face several technical challenges when detecting p53 K373 acetylation in tissues and primary cells:

Tissue-Specific Considerations:

• Variable p53 expression levels across tissues require optimization of antibody dilutions

• Formalin fixation can mask epitopes, requiring antigen retrieval optimization

• Endogenous fluorescence in certain tissues may interfere with immunofluorescence detection

• Post-mortem interval affects post-translational modification stability

Primary Cell Challenges:

• Low abundance of acetylated p53 in unstressed primary cells

• Limited cell numbers restrict protein yield for Western blotting

• Primary cultures may have heterogeneous stress responses

• Senescence during culture may alter p53 modification patterns

Methodological Solutions:

• For tissues:

  • Optimize antigen retrieval methods (citrate vs. EDTA buffers)

  • Use signal amplification systems (TSA, polymer-based detection)

  • Consider fresh-frozen samples rather than FFPE when possible

  • Employ laser-capture microdissection for region-specific analysis

• For primary cells:

  • Pre-treat with deacetylase inhibitors to preserve acetylation

  • Use flow cytometry for single-cell resolution

  • Implement proximity ligation assays for enhanced sensitivity

  • Consider in situ detection rather than protein extraction

These approaches help overcome the inherent challenges in studying p53 acetylation in more physiologically relevant systems beyond established cell lines.

How does p53 K373 acetylation respond to different types and intensities of cellular stress?

Research reveals that p53 K373 acetylation functions as a cellular "sensor" system that responds differentially to various stressors:

Stress Type Responses:

• DNA damage agents: Different damage types induce distinct K373 acetylation kinetics

  • Etoposide (topoisomerase inhibitor): Induces both K320 and K373 acetylation

  • Bizelesin (DNA crosslinker): Rapidly induces K373 acetylation

  • Adozelesin (monofunctional alkylator): Shows slower K373 acetylation kinetics

• Stress intensity correlation:

  • Higher doses of DNA-damaging agents produce greater K373 acetylation levels

  • Severe damage preferentially enhances K373 over K320 acetylation

Experimental Approaches:

• Conduct dose-response and time-course experiments with various stressors

• Compare acetylation patterns across multiple sites simultaneously

• Correlate acetylation levels with cellular outcomes (survival vs. death)

• Use pharmacological modulators to alter stress response pathways

This differential response suggests that K373 acetylation acts as part of a molecular switch that helps cells "decide" between repair/survival and apoptosis based on the type and severity of damage . For methodological consistency, researchers should carefully standardize treatment conditions when comparing K373 acetylation across experimental systems.

What are the most reliable methodologies for distinguishing between acetylation at K373 and other nearby acetylation sites?

Distinguishing between acetylation at K373 and nearby sites (particularly K372 and K382) requires careful methodological approaches:

Antibody-Based Methods:

• Use highly validated site-specific antibodies generated against synthetic acetyl-peptides derived from the region around K373

• Perform peptide competition assays to confirm specificity

• Consider antibodies raised against dual modifications (e.g., antibodies detecting both K373 and K382 acetylation)

• Validate using acetylation-deficient mutants (K373R)

Mass Spectrometry Approaches:

• Employ high-resolution MS/MS to distinguish acetylation sites based on fragment ion patterns

• Use targeted MRM for specific lysine residues

• Consider electron transfer dissociation (ETD) fragmentation for improved localization

• Pre-treat samples with deacetylase inhibitors to preserve acetylation

Genetic Approaches:

• Generate site-specific mutants (K373R) while preserving other lysines

• Create cells expressing single acetylation-mimetic mutations (K373Q)

• Use CRISPR/Cas9 to introduce specific mutations at endogenous loci